$93.97
+3.28 (+3.62%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TMDX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 12 observational · 10 with posted results
Held by 12 tracked-famous managers (CITADEL ADVISORS LLC, BAILLIE GIFFORD & CO, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., +7 more) · FINRA short interest 9.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| US National TOP RegistryNCT06513091observationalOne-year patient and graft survival | — | Recruiting | Device: OCS Lung | Lung Transplant | 10,000 | Nov 2034 | ≤ 3,024 d | 2025-09-03 |
| US National OCS Liver Perfusion (OLP) RegistryNCT05940857observationalSurvival | — | Recruiting | Device: OCS Liver | Liver Transplant | 100,000 | Oct 2031 | ≤ 1,898 d | 2024-08-16 |
| US National OCS Heart Perfusion (OHP) RegistryNCT05915299observationalRecipients' patient and graft survival | — | Recruiting | Device: OCS Heart | Heart Transplant | 100,000 | 2029-08-31 | in 1,107 d | 2025-10-30 |
| Decreasing Edema With a Novel OCS Solution TrialNCT0734071030-day patient and graft survival with freedom from PGD3Randomized · Open-label · Treatment | Not applicable | Not yet recruiting | Device: OCS Lung System · Other: Static Cold Storage | Lung Transplant | 450 | Dec 2027 | ≤ 498 d | 2026-01-14 |
| Enhancing Heart Allograft Function With the OCS Heart System TrialNCT07145515Patient and graft survivalRandomized · Open-label · Treatment | Not applicable | Recruiting | Device: OCS Heart · Other: Static Cold Storage (SCS) | Heart Transplant | 655 | 2027-01-30 | in 163 d | 2026-01-12 |
| OCS DCD Heart + CAP Continued Follow-UpNCT05741723observationalPatient survival | — | Active, not recruiting | Device: OCS Heart | Heart Transplant | 276 | Oct 2026 | ≤ 72 d | 2025-09-09 |
| OCS Heart EXPAND + CAP Continued Follow-UpNCT05096299observationalPatient survival | — | Active, not recruiting | Device: OCS Heart | Heart Transplant | 150 | Aug 2026 | ≤ 11 d | 2025-04-09 |
| OCS Heart Perfusion Post-Approval RegistryNCT05047068observationalPatient Survival | — | Active, not recruiting | Device: OCS Heart System | Transplant | 350 | Dec 2025 | — | 2025-10-30 |
| OCS™ Lung TOP Registry For Donor Lungs for TransplantationNCT03639025observational12-month patient and graft survival post double-lung transplant | — | Active, not recruiting | Device: OCS Lung System | Lung Transplantation | 458 | 2025-11-30 | — | 2025-08-27 |
| OCS Liver Perfusion (OLP) Post-Approval RegistryNCT05074160observationalPatient Survival | — | Active, not recruiting | Device: OCS Liver | Liver Transplant | 166 | 2024-03-22actual | — | 2025-04-10 |
| OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval StudyNCT05096754observationalGraft Survival | — | Completed | Device: OCS Liver | Liver Transplant | 74 | 2023-02-02actual | — | 2023-12-08 |
| OCS Liver DCD TrialNCT04194437results2025-01-17Liver Graft Survival Through 6 Months Post-transplantOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Enrollment in Liver DCD was stopped as a result of the FDA approval for the OCS Liver System and follow-up ended on 12/16/2024 based on adequate patient follow-up. | Device: OCS Liver System | Liver Transplant | 9 | 2022-03-22actual | — | 2025-09-05 |
| Donor After Circulatory Death Heart CAP TrialNCT04615182results2024-06-21Patient SurvivalOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Transplant | Heart Transplant | 90 | 2021-12-21actual | — | 2024-06-21 |
| OCS Liver PROTECT Continuation Post-Approval StudyNCT05096741observationalLiver Graft Survival | — | Completed | Device: OCS Liver | Liver Transplant | 300 | 2021-11-05actual | — | 2024-01-09 |
| INSPIRE Continuation Post-Approval StudyNCT03868904observationalBrochiolitis Obliterans Syndrome (BOS) -free survival | — | Completed | Device: OCS Lung System | Bronchiolitis Obliterans | 220 | 2021-10-12actual | — | 2022-04-07 |
| OCS Lung Expand Post-Approval Study - Expand Follow-Up Data CollectionNCT04194398observationalPatient and graft survival | — | Completed | Device: OCS Lung System | OCS Lung System | 79 | 2021-09-30actual | — | 2022-04-07 |
| Heart EXPAND Continued Access ProtocolNCT03835754results2025-01-17Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantationOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OCS Heart System | Heart Transplant | 75 | 2021-09-15actual | — | 2025-01-17 |
| Donors After Circulatory Death Heart TrialNCT03831048results2024-05-07SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OCS Heart System · Other: Cold Storage | Heart Transplant | 180 | 2021-04-01actual | — | 2024-05-07 |
| OCS Liver PROTECT Continued Access ProtocolNCT04186221results2024-07-24Participants With Early Liver Allograft Dysfunction (EAD)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OCS Liver System | Liver Transplant | 74 | 2021-02-02actual | — | 2024-07-24 |
| OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for TransplantationNCT02522871results2023-06-29Participants With Early Liver Allograft Dysfunction (EAD)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OCS™ Liver System · Other: Control | Liver Transplantation, Liver Preservation for Transplant | 300 | 2019-10-22actual | — | 2023-06-29 |
| OCS Lung System EXPAND II TrialNCT03343535results2024-02-28Patient SurvivalOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Enrollment in EXPAND II was stopped June 24, 2019 as a result of the FDA approval for the EXPAND indication. Therefore, no additional sites or subjects were enrolled after that time. | Device: OCS Lung Preservation | Lung Transplantation | 46 | 2019-08-27actual | — | 2024-02-28 |
| International EXPAND Heart Pivotal TrialNCT02323321results2025-01-17Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Preservation of Hearts for Transplantation | Heart Transplant | 75 | 2018-04-25actual | — | 2025-01-17 |
| Trial of the TransMedics Organ Care System™ Liver For Preserving and Assessing Donor Livers for TransplantationNCT02449694Number of donor livers preserved by OCS in a near physiologic state.Open-label · Treatment | Not applicable | Completed | Device: OCS Liver | Liver Preservation | 25 | 2017-09-19actual | — | 2018-04-06 |
| International EXPAND Lung Pivotal TrialNCT01963780results2022-07-07Number of Participants With Composite Endpoint of Patient Survival at Day-30 Post Transplant and Absence of Primary Graft Dysfunction (PGD) Grade 3 During the First 72 Hours Post Lung TransplantOpen-label · Treatment | Not applicable | Completed | Device: OCS Lung Preservation | Lung Transplant | 79 | 2016-11-22actual | — | 2022-07-07 |
| International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and TransplantationNCT01630434results2022-07-07A Composite of Patient Survival at Day 30 Post Transplantation, and Absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 Within the First 72 Hours Post-transplantation.Randomized · Open-label · Treatment | Not applicable | Completed | Device: OCS Lung, Cold flush and storage | Lung Preservation | 320 | Sep 2014actual | — | 2023-04-04 |
| Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual TransplantationNCT0085571230-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30Randomized · Open-label · Treatment | Not applicable | Completed | Device: Organ Care System, Cold Cardioplegia Solution | Heart Failure | 128 | Oct 2013actual | — | 2020-06-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19